None
Conditions
Interventions
Test Group:Citrate-based Hemofiltration Replacement Solution
Control Group:4% Sodium Citrate Anticoagulation
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age >=18 years, regardless of gender. 2. Hemodynamically stable and able to tolerate CVVH (Continuous Veno-Venous Hemofiltration) therapy. 3. Acute Physiology and Chronic Health Evaluation (APACHE) II score >10. 4. Signed informed consent obtained.
Exclusion criteria
Exclusion criteria: 1. History of sodium citrate allergy. 2. Contraindications to citrate anticoagulation, including: - Total bilirubin >60 µmol/L with direct bilirubin >50% - Persistent hypotension (SBP 2 hours unresponsive to vasopressors) - Refractory hypoxemia (PaO2 4 mmol/L) 3. Concurrent use of other blood purification therapies during treatment (e.g., hemoperfusion, plasma exchange, ECMO). 4. Prior use of citrate anticoagulation in CRRT before study enrollment. 5. Psychiatric disorders or other conditions impairing treatment compliance. 6. Moribund patients with expected survival <72 hours. 7. Anticipated treatment duration <48 hours. 8. Low body weight (=45 kg) with high citrate accumulation risk. 9. Pregnancy. 10. Planned organ transplantation. 11. Participation in other clinical trials. 12. Other conditions deemed by clinicians to indicate critical/unstable illness.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| 72 hour extracorporeal circulation survival rate;Hospitalization days;mortality; | — |
Primary
| Measure | Time frame |
|---|---|
| Extracorporeal Circuit Lifespan; | — |
Countries
China
Contacts
Public ContactLing Zhang
West China Hospital, Sichuan University
Outcome results
None listed